Samsung Bioepis Announces US Launch of ONTRUZANT® (trastuzumab-dttb) for Early and Metastatic HER2-overexpressing Breast Cancer and Metastatic Gastric Cancer
ONTRUZANT® is Samsung Bioepis’ first oncology biosimilar available in the United States INCHEON, Korea–(BUSINESS WIRE)– Samsung Bioepis Co., Ltd. announced today that ONTRUZANT® (trastuzumab-dttb), a...